Biotech selling small-molecule and gene-therapy drugs for rare genetic diseases, including spinal muscular atrophy and Duchenne muscular dystrophy.
Biotech selling small-molecule and gene-therapy drugs for rare genetic diseases, including spinal muscular atrophy and Duchenne muscular dystrophy.
Combines sales of its own rare-disease drugs, priced for very small patient groups and sold through specialty pharmacies, with royalties from Roche's Evrysdi, a spinal muscular atrophy drug it helped discover, which arrive without selling costs. It has sold part of that royalty stream to Royalty Pharma, and the rest helps fund its pipeline.
Moat: narrow (IP / patents, regulatory licence). Deep rare-neuromuscular-disease expertise and orphan exclusivity across a diversified genetic-disease portfolio.
Headquarters: Warren, New Jersey, United States · Founded: 1998 · Employees: 991
Size PTC Therapeutics (PTCT) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $5.03B, the 1170th largest of 3,085 United States companies the cockpit tracks. Shares closed at $60.23 on 18 Nov 2026.
Performance Over six months the shares fell 15.2%, against +10.6% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 35.0% over the last twelve months (peer median +12.1%); the operating margin is 21.6% (peer median 20.6%).
Valuation It trades at 31.2× forward earnings against a peer median of 25.8× (6th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -29 pp: the price already allows for a slowdown.
Short interest Short interest is 9.3% of the free float (30 Oct 2026).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.16B | $1.73B | $807M | $938M | $699M |
| Revenue growth | — | +115% | -14% | +34% | — |
| Gross profit | $1.03B | $1.66B | $689M | $650M | $538M |
| EBITDA | $310M | $895M | -$71.1M | -$113M | -$311M |
| Net income | -$106M | $683M | -$363M | -$627M | -$559M |
| Free cash flow | $2.07M | $702M | -$114M | -$187M | -$389M |
| Capital expenditure | $51.8M | $300M | $74.2M | $121M | $152M |
| Total debt | $636M | $399M | $389M | $415M | $704M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| PTC Therapeutics PTCT | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% |
| Sarepta Therapeutics SRPT | $1.56B | -15% | -19% | 0% | n/a | -6.8% |
| Roche RO.SW | $381B | +21% | -1% | 31% | 19.9× | 1.7% |
| Biogen BIIB | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PTCT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.3% | +0.2% | 7th lowest of 21 |
| 6-month return | -15.2% | +10.6% | 4th lowest of 21 |
| Distance from 52-week high | -33.7% | -21.1% | 8th lowest of 21 |
| Revenue growth (TTM) | -35.0% | +12.1% | lowest of 19 |
| Operating margin | 21.6% | 20.6% | 9th highest of 19 |
| Forward P/E | 31.2× | 25.8× | 6th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | 6.6% | 6.5% | 9th least demanding of 17 |
| Growth delivered (Del g) | +35.4% | +12.5% | 5th highest of 17 |
| Hurdle (Req g minus delivered) | -28.7 pp | -2.6 pp | 5th least demanding of 17 |
| EV / EBITDA | 11.4× | 22.8× | cheapest of 11 |
| Net debt / EBITDA | -4.8× | -0.7× | least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics PTCT | United States | $5.03B | -15% | -35% | 22% | 31.2× | 6.6% | +35.4% |
| SKBP 326030.KS | South Korea | $5.03B | -16% | +37% | 38% | 21.5× | -4.4% | +93.6% |
| IPCA Laboratories IPCALAB.NS | India | $5.03B | +12% | +12% | 18% | 31.1× | 16.5% | +12.2% |
| Liquidia LQDA | United States | $5.08B | -9% | +798% | 47% | 13.8× | 5.0% | +192.5% |
| Beijing TongRenTang 600085.SS | China | $4.91B | -12% | -17% | 8% | 28.7× | 1.7% | +6.2% |
| Humanwell Healthcare (Group) 600079.SS | China | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% | +3.0% |
| Erasca ERAS | United States | $4.83B | +24% | n/a | n/a | n/a | n/a | n/a |
| Travere Therapeutics TVTX | United States | $4.82B | +16% | +49% | -3% | 17.1× | 17.3% | +19.9% |
| Veradermics MANE | United States | $5.27B | +19% | n/a | n/a | n/a | n/a | n/a |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.79B | +10% | +12% | 33% | 37.3× | 26.4% | +5.5% |
| Shanghai Allist Pharmaceuticals 688578.SS | China | $5.32B | -14% | +39% | 47% | 12.4× | 0.1% | +519.6% |
| Sumitomo Pharma 4506.T | Japan | $5.33B | +11% | +11% | 10% | 8.6× | 1.7% | -2.6% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.74B | +37% | +21% | 16% | 33.6× | 15.9% | +12.7% |
| Ionis Pharmaceuticals IONS | United States | $4.56B | -64% | -1% | -59% | n/a | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Guangzhou Baiyunshan Pharmaceutical 0874.HK | Hong Kong | $4.48B | -23% | +6% | 3% | 7.0× | 1.3% | +4.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.38B | +1% | +25% | 25% | 31.7× | 23.8% | +13.8% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.36B | +12% | -4% | 32% | 16.2× | -9.9% | +0.3% |
| Camurus CAMX.ST | Sweden | $4.36B | +36% | +3% | 38% | 45.1× | 7.9% | +46.5% |